- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-297/15: Judgment of the Court (Fifth Chamber) of 10 November 2016 (request for a preliminary ruling from the Sø- og Handelsretten — Denmark) — Ferring Lægemidler A/S, acting on behalf of Ferring BV v Orifarm A/S (Reference for a preliminary ruling — Trade marks — Directive 2008/95/EC — Article 7(2) — Medicinal products — Parallel import — Partitioning of the markets — Need for the repackaging of the product bearing the mark — Medicinal product placed on the exporting market and importing market by the trade mark proprietor with the same kind of packaging)
ECLI:EU:UNKNOWN:62015CA0297
62015CA0297
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
(Case C-297/15) (*)
((Reference for a preliminary ruling - Trade marks - Directive 2008/95/EC - Article 7(2) - Medicinal products - Parallel import - Partitioning of the markets - Need for the repackaging of the product bearing the mark - Medicinal product placed on the exporting market and importing market by the trade mark proprietor with the same kind of packaging))
(2017/C 014/12)
Language of the case: Danish
Referring court
Parties to the main proceedings
Applicant: Ferring Lægemidler A/S, acting on behalf of Ferring BV
Defendant: Orifarm A/S
Operative part of the judgment
Article 7(2) of Directive 2008/95/EC of the European Parliament and of the Council of 22 October 2008 to approximate the laws of the Member States relating to trade marks must be interpreted as meaning that a trade mark proprietor may object to the continued marketing of a medicinal product by a parallel importer, where that importer has repackaged that medicinal product in a new, outer packaging and reaffixed the trade mark, where, first, the medicinal product at issue can be marketed in the importing State party to the EEA Agreement, of 2 May 1992, in the same packaging as that in which it is marketed in the exporting State party to the EEA Agreement and, second, the importer has not demonstrated that the imported product can only be marketed in a limited part of the importing State’s market, and those are matters which it is for the referring court to determine.
(*)
Language of the case: Danish